Pacira BioSciences Inc
For the period ended Jun 11, 2024. Filed Apr 22, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 11, 2024 · Filed Apr 22, 2024
Contents
V. Elements of Our Executive Compensation Program
revenue,
market capitalization, and
employee headcount.
The Compensation Committee also takes into consideration:
stage of development,
growth in revenue, and
stock price
At the time the 2023 peer group was approved by the Compensation Committee in September 2022 based on analysis and recommendations from Aon,
our market capitalization was positioned at approximately the 38 th percentile of our peer group, and our projected 2022 year-ending revenues was positioned at approximately the 69 th percentile of our peer group. The Compensation Committee believes that the companies selected to our peer group are broadly comparable to us and represent our labor market for talent for key leadership positions. Our Compensation Committee annually reviews our peer group with Aon to determine if adjustments are necessary to ensure that it continues to be relevant or if additional peer companies or groups are necessary to provide appropriate information on market practices and compensation levels.
Our peer group for 2023 compensation purposes was as follows:
| | • ACADIA Pharmaceuticals, Inc. | | | | • Emergent BioSolutions, Inc. | | | | • PTC Therapeutics, Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|
| | • Alkermes plc | | | | • Exelixis, Inc. | | | | • Sarepta Therapeutics, Inc. | |
| | • Amicus Therapeutics, Inc. | | | | • Halozyme Therapeutics, Inc. | | | | • Supernus Pharmaceuticals, Inc. | |
| | • Blueprint Medicines Corporation | | | | • Ionis Pharmaceuticals, Inc. | | | | • Travere Therapeutics, Inc. | |
| | • CareDx, Inc. | | | | • Ironwood Pharmaceuticals, Inc. | | | | • Ultragenyx Pharmaceutical, Inc. | |
| | • Corcept Therapeutics, Inc. | | | | • Natera, Inc. | | | | • United Therapeutics Corporation | |
| | • Dynavax Technologies Corporation | | | | • Organogenesis Holdings, Inc. | | | | ||
Company added to peer group for 2023
For 2023, the Compensation Committee removed Agios Pharmaceuticals, Inc., Coherus BioSciences, Inc. and Collegium Pharmaceutical, Inc. due to their revenues or market capitalization now falling significantly outside the peer group criteria, and added Dynavax Technologies Corporation, Natera, Inc., and Sarepta Therapeutics, Inc. due to being aligned to most or all the peer criteria and being potential executive talent competitors.
V.
ELEMENTS OF OUR EXECUTIVE COMPENSATION PROGRAM
The Compensation Committee reviews and considers the performance of each named executive officer and considers the amount of compensation:
we are willing to pay to retain each named executive officer;
we would have to pay to replace each named executive officer;
that the named executive officer could otherwise command in the competitive employment market.
The primary elements of our executive compensation program are:
60 | investor.pacira.com
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.